Cargando…

The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Byrne, Kenneth J., Barr, Martin P., Gray, Steven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756421/ https://www.ncbi.nlm.nih.gov/pubmed/24212667 http://dx.doi.org/10.3390/cancers3011426

Ejemplares similares

Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy
por: Lawless, Matthew W, et al.
Publicado: (2009)

IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer
por: Baird, Anne-Marie, et al.
Publicado: (2013)

Epigenetics Underpinning the Regulation of the CXC (ELR(+)) Chemokines in Non-Small Cell Lung Cancer
por: Baird, Anne-Marie, et al.
Publicado: (2011)

Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin
por: MacDonagh, Lauren, et al.
Publicado: (2021)

Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature
por: Barr, Martin P., et al.
Publicado: (2013)

Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature
por: Barr, Martin P., et al.
Publicado: (2020)

Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer
por: O'Byrne, Kenneth J., et al.
Publicado: (2011)

Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells
por: Circu, Magdalena, et al.
Publicado: (2017)

Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells
por: Circu, Magdalena, et al.
Publicado: (2018)

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
por: MacDonagh, Lauren, et al.
Publicado: (2017)

Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer
por: Paul, I, et al.
Publicado: (2012)

Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
por: Godwin, P., et al.
Publicado: (2013)

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
por: Barr, Martin P, et al.
Publicado: (2015)

Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
por: Barr, Martin P., et al.
Publicado: (2020)

Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
por: Chen, Helen H. W., et al.
Publicado: (2010)

MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer
por: MacDonagh, Lauren, et al.
Publicado: (2021)

Development and characterisation of a panel of phosphatidylinositide 3-kinase – mammalian target of rapamycin inhibitor resistant lung cancer cell lines
por: Heavey, Susan, et al.
Publicado: (2018)

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
por: Kapeleris, Joanna, et al.
Publicado: (2018)

Bone matters in lung cancer
por: Brodowicz, T., et al.
Publicado: (2012)

Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model
por: Baird, Anne-Marie, et al.
Publicado: (2016)

Cisplatin Resistance: Genetic and Epigenetic Factors Involved
por: Lugones, Yuliannis, et al.
Publicado: (2022)

The Role of Circulating Biomarkers in Lung Cancer
por: Herath, Sayuri, et al.
Publicado: (2022)

Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review
por: Fernandez, Alejandra, et al.
Publicado: (2021)

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells
por: Chun, Jaemoo
Publicado: (2023)

Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2
por: Misri, Swati, et al.
Publicado: (2022)

SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer
por: Burgess, Joshua T., et al.
Publicado: (2020)

Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance
por: Sun, Fan, et al.
Publicado: (2019)

Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy
por: Li, Heng, et al.
Publicado: (2014)

Epigenetic modification of α-N-acetylgalactosaminidase enhances cisplatin resistance in ovarian cancer
por: Ha, Ye-Na, et al.
Publicado: (2018)

Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin-resistant non-small cell lung cancer
por: Zhao, Jian, et al.
Publicado: (2020)

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer
por: Watanabe, R, et al.
Publicado: (2003)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma
por: Marayati, Raoud, et al.
Publicado: (2021)

Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
por: Kulasinghe, Arutha, et al.
Publicado: (2019)

Potential Role of GST-π in Lung Cancer Stem Cell Cisplatin Resistance
por: Wang, Wenjun, et al.
Publicado: (2021)

Epigenetic Regulation of RIP3 Suppresses Necroptosis and Increases Resistance to Chemotherapy in NonSmall Cell Lung Cancer
por: Wang, Qiong, et al.
Publicado: (2019)

The role of inner nuclear membrane proteins in tumourigenesis and as potential targets for cancer therapy
por: Rose, Maddison, et al.
Publicado: (2022)

Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1)
por: Gu, Yixue, et al.
Publicado: (2017)

Erratum to: Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy
por: Li, Heng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9eluk846u651p2c1117sc6b0lc